Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georgina Torrandell-Haro

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Frontiers in Psychiatry|March 15, 2024
Association between CNS-active drugs and risk of Alzheimer's and age-related neurodegenerative diseasesHelena Cortes-Flores, Georgina Torrandell-Haro, Roberta Diaz Brinton
Medrxiv : the Preprint Server for Health Sciences|March 13, 2026
Immunotherapies for risk reduction in age-associated neurodegenerative diseases: impact of sex and treatment durationHelena Cortes-Flores, Georgina Torrandell-Haro, Roberta Diaz Brinton
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentHelena Cortes-Flores, Georgina Torrandell-Haro, Roberta Diaz Brinton
Frontiers in Aging Neuroscience|June 3, 2026
Anti-inflammatory and immunomodulatory therapies are associated with reduced risk of age-associated neurodegenerative diseases: impact of sex and treatment durationHelena Cortes-Flores, Georgina Torrandell-Haro, Roberta Diaz Brinton
Alzheimer'S & Dementia (New York, N. Y.)|March 28, 2025
Combination therapy targeting Alzheimer's disease risk factors is associated with a significant delay in Alzheimer's disease-related cognitive declineYuan Shang, Georgina Torrandell-Haro, Francesca Vitali, et al.
Frontiers in Aging Neuroscience|May 23, 2022
Association Between Specific Type 2 Diabetes Therapies and Risk of Alzheimer's Disease and Related Dementias in Propensity-Score Matched Type 2 Diabetic PatientsGeorgina Torrandell-Haro, Gregory L Branigan, Roberta Diaz Brinton, et al.
Heliyon|November 3, 2022
Age and sex differences on anti-hyperglycemic medication exposure and risk of newly diagnosed multiple sclerosis in propensity score matched type 2 diabeticsGregory L Branigan, Georgina Torrandell-Haro, Francesca Vitali, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 7, 2020
Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseasesGeorgina Torrandell-Haro, Gregory L Branigan, Francesca Vitali, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 9, 2025
Carotid endarterectomy mitigates Alzheimer's disease and non-Alzheimer's disease dementia risk linked to asymptomatic carotid stenosisFrancesca Vitali, Georgina Torrandell-Haro, Juan C Arias, et al.
Cancer Medicine|March 16, 2022
Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancerGregory L Branigan, Georgina Torrandell-Haro, Maira Soto, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Frontiers in Psychiatry|March 15, 2024
Association between CNS-active drugs and risk of Alzheimer's and age-related neurodegenerative diseasesHelena Cortes-Flores, Georgina Torrandell-Haro, Roberta Diaz Brinton
Medrxiv : the Preprint Server for Health Sciences|March 13, 2026
Immunotherapies for risk reduction in age-associated neurodegenerative diseases: impact of sex and treatment durationHelena Cortes-Flores, Georgina Torrandell-Haro, Roberta Diaz Brinton
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentHelena Cortes-Flores, Georgina Torrandell-Haro, Roberta Diaz Brinton
Frontiers in Aging Neuroscience|June 3, 2026
Anti-inflammatory and immunomodulatory therapies are associated with reduced risk of age-associated neurodegenerative diseases: impact of sex and treatment durationHelena Cortes-Flores, Georgina Torrandell-Haro, Roberta Diaz Brinton
Alzheimer'S & Dementia (New York, N. Y.)|March 28, 2025
Combination therapy targeting Alzheimer's disease risk factors is associated with a significant delay in Alzheimer's disease-related cognitive declineYuan Shang, Georgina Torrandell-Haro, Francesca Vitali, et al.
Frontiers in Aging Neuroscience|May 23, 2022
Association Between Specific Type 2 Diabetes Therapies and Risk of Alzheimer's Disease and Related Dementias in Propensity-Score Matched Type 2 Diabetic PatientsGeorgina Torrandell-Haro, Gregory L Branigan, Roberta Diaz Brinton, et al.
Heliyon|November 3, 2022
Age and sex differences on anti-hyperglycemic medication exposure and risk of newly diagnosed multiple sclerosis in propensity score matched type 2 diabeticsGregory L Branigan, Georgina Torrandell-Haro, Francesca Vitali, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 7, 2020
Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseasesGeorgina Torrandell-Haro, Gregory L Branigan, Francesca Vitali, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 9, 2025
Carotid endarterectomy mitigates Alzheimer's disease and non-Alzheimer's disease dementia risk linked to asymptomatic carotid stenosisFrancesca Vitali, Georgina Torrandell-Haro, Juan C Arias, et al.
Cancer Medicine|March 16, 2022
Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancerGregory L Branigan, Georgina Torrandell-Haro, Maira Soto, et al.
Pageof 2